TECHNOLOGY

BRGs: a new family of drugs with two major components

CENTRAL COMPONENT

The central components of the BRG family of drugs are FDA approved scaffolds that can vary as needed to achieve desired pharmacokinetic properties and/or cell targeting.

OUTER COMPONENT

The outer component of the BRG family of drugs is part of a drug already approved by the FDA.

COMBINING

BHCRG is the first to combine these two components to make a new drug family. Multiple variations are possible. For example, molecular weights can vary from less than 500 up to 100,000 Daltons.

INNOVATION

The BRGs are new, but the components are well known. This new drug family has novel, unexpected features. BRGs are being tested for synergistic effects with other anticancer agents.